Difference between revisions of "Non-small cell lung cancer, HER2-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
|||
Line 18: | Line 18: | ||
=Metastatic disease, all lines of therapy= | =Metastatic disease, all lines of therapy= | ||
+ | ==Carboplatin, Pemetrexed, Pembrolizumab {{#subobject:a3c8c5|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:04328c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.clinicaltrials.gov/study/NCT05048797 Awaiting publication (DESTINY-Lung04)] | ||
+ | |2021-ongoing | ||
+ | |style="background-color:#1a9851"|Phase 3 (C) | ||
+ | |[[#Trastuzumab_deruxtecan_monotherapy|T-DXd]] | ||
+ | |style="background-color:#d3d3d3"|TBD if different primary endpoint of PFS | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] | ||
+ | *[[Pemetrexed (Alimta)]] | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''DESTINY-Lung04:''' [https://clinicaltrials.gov/study/NCT05048797 NCT05048797] | ||
+ | ==Cisplatin, Pemetrexed, Pembrolizumab {{#subobject:a3csc5|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:04sp8c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.clinicaltrials.gov/study/NCT05048797 Awaiting publication (DESTINY-Lung04)] | ||
+ | |2021-ongoing | ||
+ | |style="background-color:#1a9851"|Phase 3 (C) | ||
+ | |[[#Trastuzumab_deruxtecan_monotherapy|T-DXd]] | ||
+ | |style="background-color:#d3d3d3"|TBD if different primary endpoint of PFS | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] | ||
+ | *[[Pemetrexed (Alimta)]] | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''DESTINY-Lung04:''' [https://clinicaltrials.gov/study/NCT05048797 NCT05048797] | ||
==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}== | ==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> |
Revision as of 15:15, 13 August 2023
Page editor | Section editor | ||
---|---|---|---|
Eric K. Singhi, MD MD Anderson Cancer Center Houston, TX, USA |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
4 variants on this page
|
Guidelines
ASCO
- 2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
ESMO
- 2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Metastatic disease, all lines of therapy
Carboplatin, Pemetrexed, Pembrolizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (DESTINY-Lung04) | 2021-ongoing | Phase 3 (C) | T-DXd | TBD if different primary endpoint of PFS |
References
- DESTINY-Lung04: NCT05048797
Cisplatin, Pemetrexed, Pembrolizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (DESTINY-Lung04) | 2021-ongoing | Phase 3 (C) | T-DXd | TBD if different primary endpoint of PFS |
References
- DESTINY-Lung04: NCT05048797
Trastuzumab deruxtecan monotherapy
Regimen variant #1, 5.4 mg/kg
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 (RT) |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 5.4 mg/kg IV once on day 1
21-day cycles
Regimen variant #2, 6.4 mg/kg
Study | Dates of enrollment | Evidence |
---|---|---|
Li et al. 2021 (DESTINY-Lung01) | 2018-2020 | Phase 2 |
Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 6.4 mg/kg IV once on day 1
21-day cycles
References
- DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03505710
- DESTINY-Lung02: NCT04644237